NYXH Stock Chart & Stats
$1.40
$0.00(0.00%)
At close: 4:00 PM EDT
$1.40
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.26 - $8.59
Previous Close$1.4
Volume58.96K
Average Volume (3M)38.97K
Market Cap
$143.16M
Enterprise Value$115.85
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 05, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding100,072,815
10 Day Avg. Volume31,997
30 Day Avg. Volume38,970
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.28Price Target Upside205.95% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market PotentialThe target market for Genio in the U.S. is approximately 510,000 patients, representing an annual total addressable market of approximately $10 billion.
Regulatory MilestonesThe FDA has issued an Approvable Letter for Nyxoah's Genio system, indicating a positive step towards full market approval.
Bears Say
Regulatory DelaysThere is an issue with the FDA’s acceptance of data regarding manufacturing processes, delaying the anticipated approval.
Sales Performance4Q24 Genio sales were below estimates, with reported sales of €1.3M compared to an expected €2.4M.
Nyxoah News
NYXH FAQ
What was Nyxoah’s price range in the past 12 months?
Nyxoah lowest stock price was $1.26 and its highest was $8.59 in the past 12 months.
What is Nyxoah’s market cap?
Nyxoah’s market cap is $143.16M.
When is Nyxoah’s upcoming earnings report date?
Nyxoah’s upcoming earnings report date is Aug 05, 2026 which is in 4 days.
How were Nyxoah’s earnings last quarter?
Nyxoah released its earnings results on May 12, 2026. The company reported -$0.426 earnings per share for the quarter, beating the consensus estimate of -$0.579 by $0.153.
Is Nyxoah overvalued?
According to Wall Street analysts Nyxoah’s price is currently Undervalued.
Does Nyxoah pay dividends?
Nyxoah does not currently pay dividends.
What is Nyxoah’s EPS estimate?
Nyxoah’s EPS estimate is -0.45.
How many shares outstanding does Nyxoah have?
Nyxoah has 100,072,815 shares outstanding.
What happened to Nyxoah’s price movement after its last earnings report?
Nyxoah reported an EPS of -$0.426 in its last earnings report, beating expectations of -$0.579. Following the earnings report the stock price went up 0.326%.
Which hedge fund is a major shareholder of Nyxoah?
Currently, no hedge funds are holding shares in NYXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nyxoah Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.28 (205.95% Upside)
$4.28 (205.95% Upside)
Blogger Sentiment
Neutral
NYXH Sentiment 50%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 17.0 Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.40%
Trailing 12-Months
Company Description
Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
NYXH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid commercial progress and encouraging leading indicators: sequential worldwide revenue growth (+13%), strong U.S. momentum (+25% U.S. sequential), expanding surgeon/account footprint, a large prior-authorization funnel, and reimbursement clarity (CMS C-codes and 100% prior-authorization approvals reported). Management provided growth guidance and a clear product roadmap (Genio 2.2) expected to materially improve gross margins in 2027. Offsetting risks are near-term gross margin pressure from resolved production yield issues (Q1 margin 57% vs 62% prior), increased operating expenses to support the U.S. launch, and cash/runway considerations given modest cash on hand and substantial FY OpEx guidance. On balance the progress on commercialization, reimbursement de-risking, and product roadmap outweigh the near-term margin and cash challenges.View all NYXH earnings summariesNYXH Stock 12 Month Forecast
Average Price Target
$4.28
▲(205.95% Upside)
Technical Analysis
Irhythm Technologies
―
Inspire Medical Systems
―
Senseonics Holdings
―
Stereotaxis
―
NovoCure
―
Smith & Nephew Snats
―
Ownership Overview
―
Insiders
0.36% Mutual Funds
0.65% Other Institutional Investors
98.99% Public Companies and
Individual Investors